##analysisDate=2017-06-28-12-48-32000
##analyzedBy=RingStudy Site E
##exportDate=2017-11-08-12-56-31000
##analysisName=Sample 6-PHASE1
##workflowName=Oncomine Focus w2.1 - DNA and Fusions - Single Sample
##sampleNames=Site E-R5-Sample 6-F-D_v1:Site E-R1-Sample 6-F-R_RNA_v1
##reference=hg19
##variantGroup=DEFAULT
##filterChain=Site D_NoRef
##searchText=
##chromosome=All
##totalVariantCount=831
##filterInCount=17
##filteredOutCount=814
##hiddenVariantCount=0
Locus	Genotype	Ref	Type	No Call Reason	Genes	Location	Length	Oncomine Variant Class	Oncomine Gene Class	Copy Number	CytoBand	Info	Variant ID	Variant Name	% Frequency	Amino Acid Change	Read Counts	Coverage	Allele Ratio	CNV Confidence	Detection	3'/5' Imbalance	COSMIC/NCBI	Read Counts Per Million	Strand	Exon	Transcript	Coding	Variant Effect	PhyloP	SIFT	Grantham	PolyPhen	PFAM	dbSNP	DGV	MAF	EMAF	AMAF	GMAF	UCSC Common SNPs	Gene Ontology	DrugBank	ClinVar	p-value	Phred QUAL Score	Allele Coverage	CNV Precision	Ref+/Ref-/Var+/Var-	Homopolymer Length	Tiles
chr1:65310489	T/C	T	SNV		JAK1	exonic	1								50.68	p.(=)		1997	T=0.4932, C=0.5068		Present				-	16	NM_002227.2	c.2199A>G	synonymous	-4.13				Protein kinase domain,Protein tyrosine kinase	rs2230588		0.352 (ref)	0.2323	0.418	0.3492	YES	ATP binding,cytokine-mediated signaling pathway,cytoplasm,cytoskeleton,cytosol,endomembrane system,growth hormone receptor binding,interferon-gamma-mediated signaling pathway,intracellular protein kinase cascade,intracellular signal transduction,membrane,non-membrane spanning protein tyrosine kinase activity,nucleotide binding,nucleus,protein binding,protein phosphorylation,protein tyrosine kinase activity,regulation of interferon-gamma-mediated signaling pathway,regulation of type I interferon-mediated signaling pathway,response to antibiotic,type I interferon-mediated signaling pathway	2-(1,1-DIMETHYLETHYL)9-FLUORO-3,6-DIHYDRO-7H-BENZH-IMIDAZ4,5-FISOQUINOLIN-7-ONE,3-{(3R,4R)-4-methyl-3-methyl(7H-pyrrolo2,3-dpyrimidin-4-yl)aminopiperidin-1-yl}-3-oxopropanenitrile		0.00001	7875.83	T=985, C=1012		T=559/426, C=594/418	1	
chr1:156834532, chr1:156851323			ASSAYS_5P_3P		NTRK1								NTRK1.5p.eNST00000392302.e2e3,NTRK1.3p.eNST00000392302.e17e18				2,572				NoCall	0.0026		8.8782e-12,2.5392e-09																						0.0					
chr2:29416572	C/C	T	SNV		ALK	exonic	1								100.00	p.Ile1461Val		1996	T=0.0, C=1.0		Present				-	29	NM_004304.4	c.4381A>G	missense	-0.25	1.0	29.0	0.0	MAM domain,Protein kinase domain,Protein tyrosine kinase	rs1670283		0.007 (ref)	3.0E-4	0.0279	0.0097		ATP binding,NF-kappaB-inducing kinase activity,activation of MAPK activity,cell proliferation,integral to plasma membrane,neuron development,nucleotide binding,phosphorylation,plasma membrane,positive regulation of NF-kappaB transcription factor activity,protein autophosphorylation,receptor activity,regulation of apoptotic process,signal transduction,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway			0.00001	26878.5	T=0, C=1996		T=0/0, C=920/1076	1	
chr2:209113192	G/A	G	SNV		IDH1	exonic	1								47.47	p.(=)		1999	G=0.5253, A=0.4747		Present				-	4	NM_005896.3	c.315C>T	synonymous	1.35				Isocitrate/isopropylmalate dehydrogenase	rs11554137		0.049 (ref)	0.0531	0.106	0.071	YES	2-oxoglutarate metabolic process,NAD binding,NADPH regeneration,carbohydrate metabolic process,cellular lipid metabolic process,cytoplasm,cytosol,glutathione metabolic process,glyoxylate cycle,isocitrate dehydrogenase (NADP+) activity,isocitrate metabolic process,magnesium ion binding,mitochondrion,oxidoreductase activity,oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor,peroxisomal matrix,peroxisome,protein homodimerization activity,response to oxidative stress,tricarboxylic acid cycle	2'-Monophosphoadenosine 5'-Diphosphoribose,Isocitric Acid		0.00001	7035.9	G=1050, A=949		G=589/461, A=537/412	1	
chr3:178952085	A/G	A	SNV		PIK3CA	exonic	1	Hotspot	Gain-of-function			HS	COSM249874;COSM775;COSM776		C=0.00, G=29.11, T=0.00	p.His1047Arg		1999	A=0.7089, C=0.0, G=0.2911, T=0.0		Present				+	21	NM_006218.2	c.3140A>G	missense	2.33	0.01	29.0	0.639	PI3-kinase family,Phosphatidylinositol 3- and 4-kinase,Phosphoinositide 3-kinase C2,Phosphoinositide 3-kinase family	rs121913279							1-phosphatidylinositol-3-kinase activity,ATP binding,T cell costimulation,T cell receptor signaling pathway,angiogenesis,anti-apoptosis,blood coagulation,cytosol,epidermal growth factor receptor signaling pathway,fibroblast growth factor receptor signaling pathway,glucose metabolic process,hypomethylation of CpG island,insulin receptor signaling pathway,insulin receptor substrate binding,kinase activity,lamellipodium,leukocyte migration,nerve growth factor receptor signaling pathway,nucleotide binding,phosphatidylinositol 3-kinase complex,phosphatidylinositol phosphorylation,phosphatidylinositol-4,5-bisphosphate 3-kinase activity,phosphatidylinositol-mediated signaling,phosphotransferase activity, alcohol group as acceptor,platelet activation,positive regulation of peptidyl-serine phosphorylation,protein binding,protein kinase B signaling cascade,protein kinase activator activity,protein phosphorylation,protein serine/threonine kinase activity,regulation of multicellular organism growth,signal transduction	(1S,6BR,9AS,11R,11BR)-9A,11B-DIMETHYL-1-(METHYLOXY)METHYL-3,6,9-TRIOXO-1,6,6B,7,8,9,9A,10,11,11B-DECAHYDRO-3H-FURO4,3,2-DEINDENO4,5-H2BENZOPYRAN-11-YL ACETATE	other	0.00001	3489.83	A=1417, C=0, G=582, T=0		A=655/762, C=0/0, G=283/299, T=0/0	1,1,1	
chr3:182683469	C/T	C	SNV		DCUN1D1	exonic	1								25.03	p.Ala26Thr		803	C=0.7497, T=0.2503		Present				-	2	NM_020640.2	c.76G>A	missense	2.76	0.0	58.0	0.996	Cullin binding								biological_process,protein binding,ubiquitin ligase complex			0.00001	887.271	C=602, T=201		C=337/265, T=124/77	1	
chr4:1807894	A/A	G	SNV		FGFR3	exonic	1								100.00	p.(=)		1721	G=0.0, A=1.0		Present				+	14	NM_000142.4	c.1953G>A	synonymous	0.05				Immunoglobulin I-set domain,Immunoglobulin domain,Protein kinase domain,Protein tyrosine kinase	rs7688609		0.042 (ref)	8.0E-4	0.131	0.0449	YES	ATP binding,JAK-STAT cascade,MAPKKK cascade,bone maturation,bone morphogenesis,chondrocyte differentiation,chondrocyte proliferation,cytoplasmic membrane-bounded vesicle,endochondral bone growth,endochondral ossification,endoplasmic reticulum,fibroblast growth factor binding,fibroblast growth factor receptor signaling pathway,fibroblast growth factor-activated receptor activity,focal adhesion,insulin receptor signaling pathway,integral to plasma membrane,negative regulation of developmental growth,nucleotide binding,peptidyl-tyrosine phosphorylation,plasma membrane,positive regulation of ERK1 and ERK2 cascade,positive regulation of MAPKKK cascade,positive regulation of cell proliferation,positive regulation of phosphatidylinositol 3-kinase activity,positive regulation of phospholipase activity,positive regulation of tyrosine phosphorylation of Stat1 protein,positive regulation of tyrosine phosphorylation of Stat3 protein,protein autophosphorylation,protein binding,protein tyrosine kinase activity,receptor activity,regulation of apoptotic process,skeletal system development	Palifermin,Pazopanib		0.00001	23166.6	G=0, A=1721		G=0/0, A=936/785	1	
chr4:55141055	G/G	A	SNV		PDGFRA	exonic	1								100.00	p.(=)		1998	A=0.0, G=1.0		Present				+	12	NM_006206.4	c.1701A>G	synonymous	-5.31				Immunoglobulin I-set domain,Immunoglobulin domain,Protein kinase domain,Protein tyrosine kinase	rs121913270,rs121913271,rs1873778		0.037 (ref)	0.0015	0.1185	0.0411	YES	ATP binding,Leydig cell differentiation,adrenal gland development,cardiac myofibril assembly,cell activation,cell chemotaxis,cellular response to amino acid stimulus,cytoplasm,elevation of cytosolic calcium ion concentration,embryonic cranial skeleton morphogenesis,embryonic digestive tract morphogenesis,embryonic skeletal system morphogenesis,estrogen metabolic process,extracellular matrix organization,face morphogenesis,female gonad development,gliogenesis,growth factor binding,in utero embryonic development,inner ear development,integral to plasma membrane,intrinsic to plasma membrane,lung development,luteinization,male genitalia development,metanephric glomerular capillary formation,multicellular organismal development,negative regulation of platelet activation,nucleotide binding,nucleus,odontogenesis of dentin-containing tooth,palate development,peptidyl-tyrosine phosphorylation,phosphatidylinositol 3-kinase binding,phosphatidylinositol-mediated signaling,plasma membrane,platelet aggregation,platelet-derived growth factor alpha-receptor activity,platelet-derived growth factor binding,platelet-derived growth factor receptor binding,platelet-derived growth factor receptor signaling pathway,platelet-derived growth factor receptor-alpha signaling pathway,positive regulation of DNA replication,positive regulation of ERK1 and ERK2 cascade,positive regulation of cell migration,positive regulation of cell proliferation,positive regulation of fibroblast proliferation,positive regulation of phosphatidylinositol 3-kinase activity,positive regulation of phosphatidylinositol 3-kinase cascade,positive regulation of phospholipase C activity,protein autophosphorylation,protein homodimerization activity,protein tyrosine kinase activity,receptor activity,regulation of actin cytoskeleton reorganization,regulation of chemotaxis,regulation of mesenchymal stem cell differentiation,response to cytokine stimulus,response to estradiol stimulus,response to hormone stimulus,response to hyperoxia,response to inorganic substance,retina vasculature development in camera-type eye,signal transduction involved in regulation of gene expression,transmembrane receptor protein tyrosine kinase activity,vascular endothelial growth factor receptor signaling pathway,vascular endothelial growth factor-activated receptor activity,wound healing	Becaplermin,Imatinib,Pazopanib,Sunitinib		0.00001	26928.4	A=0, G=1998		A=0/0, G=1121/877	1	
chr5:176517985	A/G	A	SNV		FGFR4	exonic	1								18.16	p.(=)		1503	A=0.8184, G=0.1816		Present				+	5	NM_213647.1	c.483A>G	synonymous	-3.74				Immunoglobulin I-set domain,Immunoglobulin V-set domain,Immunoglobulin domain,Protein kinase domain,Protein tyrosine kinase								ATP binding,alveolar secondary septum development,cell migration,cell-cell junction,cytoplasm,endoplasmic reticulum,endosome,extracellular region,fibroblast growth factor 1 binding,fibroblast growth factor 2 binding,fibroblast growth factor binding,fibroblast growth factor receptor signaling pathway,fibroblast growth factor-activated receptor activity,glucose homeostasis,heparin binding,insulin receptor signaling pathway,integral to plasma membrane,lung development,nucleolus,nucleotide binding,nucleus,organ induction,peptidyl-tyrosine phosphorylation,phosphate ion homeostasis,plasma membrane,positive regulation of DNA biosynthetic process,positive regulation of ERK1 and ERK2 cascade,positive regulation of cell proliferation,positive regulation of metalloenzyme activity,positive regulation of proteolysis,protein autophosphorylation,protein tyrosine kinase activity,receptor activity,regulation of bile acid biosynthetic process,regulation of cholesterol homeostasis,regulation of extracellular matrix disassembly,regulation of lipid metabolic process	Palifermin		0.00001	856.162	A=1230, G=273		A=676/554, G=264/9	1	
chr6:117711009, chr6:117632280			ASSAYS_5P_3P		ROS1								ROS1.5p_NM_002944.2.e11e12,ROS1.3p_NM_002944.2.e38e39				137,392				Absent, LOW_5P_3P_IMBALANCE_SCORE	0.0012		6.0816e-10,1.7401e-09																						0.0					
chr7:55249063	A/A	G	SNV		EGFR,EGFR-AS1	exonic, exonic_nc	1								100.00	p.(=)		1996	G=0.0, A=1.0		Present				+, -	20	NM_005228.3, NR_047551.1	c.2361G>A	synonymous	2.8				Furin-like cysteine rich region,Protein kinase domain,Protein tyrosine kinase,Receptor L domain	rs1050171		0.418 (ref)	0.3962	0.4226	0.4576	YES	AP-2 adaptor complex,ATP binding,Golgi apparatus,Golgi membrane,MAP/ERK kinase kinase activity,Shc-EGFR complex,actin filament binding,activation of phospholipase A2 activity by calcium-mediated signaling,activation of phospholipase C activity,axon guidance,basolateral plasma membrane,cell morphogenesis,cell proliferation,cell surface receptor linked signaling pathway,cell-cell adhesion,cerebral cortex cell migration,cytoplasm,digestive tract morphogenesis,double-stranded DNA binding,embryonic placenta development,endocytic vesicle,endoplasmic reticulum,endoplasmic reticulum membrane,endosome,endosome membrane,enzyme binding,epidermal growth factor receptor signaling pathway,epidermal growth factor-activated receptor activity,extracellular region,extracellular space,hair follicle development,identical protein binding,integral to membrane,intracellular,membrane,membrane raft,morphogenesis of an epithelial fold,multicellular organismal development,negative regulation of apoptotic process,negative regulation of epidermal growth factor receptor signaling pathway,negative regulation of protein catabolic process,nitric-oxide synthase regulator activity,nuclear membrane,nucleotide binding,nucleus,ossification,perinuclear region of cytoplasm,plasma membrane,positive regulation of DNA repair,positive regulation of DNA replication,positive regulation of MAP kinase activity,positive regulation of catenin import into nucleus,positive regulation of cell migration,positive regulation of cell proliferation,positive regulation of cyclin-dependent protein kinase activity involved in G1/S,positive regulation of epithelial cell proliferation,positive regulation of fibroblast proliferation,positive regulation of nitric oxide biosynthetic process,positive regulation of phosphorylation,positive regulation of protein kinase B signaling cascade,protein autophosphorylation,protein binding,protein heterodimerization activity,protein insertion into membrane,protein phosphatase binding,protein tyrosine kinase activity,receptor activity,receptor signaling protein tyrosine kinase activity,regulation of nitric-oxide synthase activity,regulation of peptidyl-tyrosine phosphorylation,response to UV-A,response to stress,salivary gland morphogenesis,signal transducer activity,signal transduction,transmembrane receptor protein tyrosine kinase activity,transmembrane signaling receptor activity	Cetuximab,Erlotinib,Flavopiridol,Gefitinib,Lapatinib,Lidocaine,N-4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL-ACRYLAMIDE,Panitumumab,S-{3-(4-ANILINOQUINAZOLIN-6-YL)AMINO-3-OXOPROPYL}-L-CYSTEINE,Trastuzumab,ZD-6474		0.00001	26856.4	G=0, A=1996		G=0/0, A=1068/928	1	
chr7:140453116	A/T	A	SNV		BRAF	exonic	1								42.28	p.Ser607Thr		1996	A=0.5772, T=0.4228		Present				-	15	NM_004333.4	c.1819T>A	missense	2.17	0.0	58.0	0.026	C1-like domain,Phorbol esters/diacylglycerol binding domain (C1 domain),Protein kinase domain,Protein tyrosine kinase,Raf-like Ras-binding domain								ATP binding,MAP kinase kinase kinase activity,activation of MAPKK activity,anti-apoptosis,cytoplasm,cytosol,metal ion binding,mitogen-activated protein kinase kinase binding,negative regulation of apoptotic process,negative regulation of neuron apoptosis,nerve growth factor receptor signaling pathway,nucleotide binding,nucleus,organ morphogenesis,plasma membrane,positive regulation of ERK1 and ERK2 cascade,positive regulation of peptidyl-serine phosphorylation,protein binding,protein heterodimerization activity,protein kinase activity,protein phosphorylation,protein serine/threonine kinase activity,receptor signaling protein activity,response to cAMP,response to peptide hormone stimulus,small GTPase mediated signal transduction,soluble fraction,synaptic transmission,synaptosome	(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime,N-{2,4-difluoro-3-(5-pyridin-3-yl-1H-pyrrolo2,3-bpyridin-3-yl)carbonylphenyl}ethanesulfonamide,N-{3-(5-chloro-1H-pyrrolo2,3-bpyridin-3-yl)carbonyl-2,4-difluorophenyl}propane-1-sulfonamide,Sorafenib		0.00001	5745.02	A=1152, T=844		A=571/581, T=435/409	1	
chr7:140453136	ACTG/TCTG	ACTG	SNV		BRAF	exonic	1	Hotspot	Gain-of-function			HS	COSM26504;COSM6137;COSM18443;COSM476;COSM1583011;COSM474;COSM249889;COSM473;COSM1127;COSM1735763		ACTGTAGCTAGACCAAAATCTG=0.00, CCTG=0.00, GCTG=0.00, TCTG=43.45, CGTG=0.00, CTTG=0.00, TGTG=0.00, TTTG=0.00, CTCG=0.00, TTTA=0.00	p.Val600Glu		1991	ACTG=0.5655, ACTGTAGCTAGACCAAAATCTG=0.0, CCTG=0.0, GCTG=0.0, TCTG=0.4345, CGTG=0.0, CTTG=0.0, TGTG=0.0, TTTG=0.0, CTCG=0.0, TTTA=0.0		Present				-	15	NM_004333.4	c.1799T>A	missense	2.17,2.69,2.17,2.69	0.0	121.0	0.971	C1-like domain,Phorbol esters/diacylglycerol binding domain (C1 domain),Protein kinase domain,Protein tyrosine kinase,Raf-like Ras-binding domain	rs113488022,rs121913227,rs121913374,rs121913375,rs121913377,rs121913378							ATP binding,MAP kinase kinase kinase activity,activation of MAPKK activity,anti-apoptosis,cytoplasm,cytosol,metal ion binding,mitogen-activated protein kinase kinase binding,negative regulation of apoptotic process,negative regulation of neuron apoptosis,nerve growth factor receptor signaling pathway,nucleotide binding,nucleus,organ morphogenesis,plasma membrane,positive regulation of ERK1 and ERK2 cascade,positive regulation of peptidyl-serine phosphorylation,protein binding,protein heterodimerization activity,protein kinase activity,protein phosphorylation,protein serine/threonine kinase activity,receptor signaling protein activity,response to cAMP,response to peptide hormone stimulus,small GTPase mediated signal transduction,soluble fraction,synaptic transmission,synaptosome	(1E)-5-(1-piperidin-4-yl-3-pyridin-4-yl-1H-pyrazol-4-yl)-2,3-dihydro-1H-inden-1-one oxime,N-{2,4-difluoro-3-(5-pyridin-3-yl-1H-pyrrolo2,3-bpyridin-3-yl)carbonylphenyl}ethanesulfonamide,N-{3-(5-chloro-1H-pyrrolo2,3-bpyridin-3-yl)carbonyl-2,4-difluorophenyl}propane-1-sulfonamide,Sorafenib	other,pathogenic	0.00001	6902.47	ACTG=1126, ACTGTAGCTAGACCAAAATCTG=0, CCTG=0, GCTG=0, TCTG=865, CGTG=0, CTTG=0, TGTG=0, TTTG=0, CTCG=0, TTTA=0		ACTG=559/567, ACTGTAGCTAGACCAAAATCTG=0/0, CCTG=0/0, GCTG=0/0, TCTG=430/435, CGTG=0/0, CTTG=0/0, TGTG=0/0, TTTG=0/0, CTCG=0/0, TTTA=0/0	1,1,1,1,1,1,1,1,1,1	
chr10:43606730, chr10:43622086			ASSAYS_5P_3P		RET								RET.5p_NM_020975.4.e6e7,RET.3p_NM_020975.4.e18e19				1238,2180				Absent, LOW_5P_3P_IMBALANCE_SCORE	0.0043		5.4956e-09,9.6772e-09																						0.0					
chr10:43613843	G/T	G	SNV		RET	exonic	1								49.62	p.(=)		1999	G=0.5038, T=0.4962		Present				+	13	NM_020975.4	c.2307G>T	synonymous	1.34				Cadherin domain,Protein kinase domain,Protein tyrosine kinase	rs1800861		0.277 (ref)	0.2347	0.1246	0.1974	YES	ATP binding,MAPKKK cascade,calcium ion binding,cellular response to retinoic acid,embryonic epithelial tube formation,endosome membrane,enteric nervous system development,homophilic cell adhesion,induction of apoptosis,integral to membrane,integral to plasma membrane,membrane,membrane protein proteolysis,nervous system development,neural crest cell migration,neuron maturation,nucleotide binding,positive regulation of cell adhesion mediated by integrin,positive regulation of cell migration,positive regulation of metanephric glomerulus development,positive regulation of neuron projection development,positive regulation of transcription, DNA-dependent,posterior midgut development,protein binding,protein phosphorylation,protein tyrosine kinase activity,receptor activity,regulation of cell adhesion,response to pain,signal transduction,transmembrane receptor protein tyrosine kinase activity,ureteric bud development	1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo3,4-DPyrimidin-4-Ylamine,4-BROMO-2-FLUORO-N-(4E)-6-METHOXY-7-(1-METHYLPIPERIDIN-4-YL)METHOXYQUINAZOLIN-4(1H)-YLIDENEANILINE,Imatinib	untested	0.00001	7598.39	G=1007, T=992		G=482/525, T=460/532	1	
chr10:43615633	C/G	C	SNV		RET	exonic	1								48.50	p.(=)		2000	C=0.515, G=0.485		Present				+	15	NM_020975.4	c.2712C>G	synonymous	0.73				Cadherin domain,Protein kinase domain,Protein tyrosine kinase	rs1800863		0.16 (ref)	0.1866	0.111	0.1609	YES	ATP binding,MAPKKK cascade,calcium ion binding,cellular response to retinoic acid,embryonic epithelial tube formation,endosome membrane,enteric nervous system development,homophilic cell adhesion,induction of apoptosis,integral to membrane,integral to plasma membrane,membrane,membrane protein proteolysis,nervous system development,neural crest cell migration,neuron maturation,nucleotide binding,positive regulation of cell adhesion mediated by integrin,positive regulation of cell migration,positive regulation of metanephric glomerulus development,positive regulation of neuron projection development,positive regulation of transcription, DNA-dependent,posterior midgut development,protein binding,protein phosphorylation,protein tyrosine kinase activity,receptor activity,regulation of cell adhesion,response to pain,signal transduction,transmembrane receptor protein tyrosine kinase activity,ureteric bud development	1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo3,4-DPyrimidin-4-Ylamine,4-BROMO-2-FLUORO-N-(4E)-6-METHOXY-7-(1-METHYLPIPERIDIN-4-YL)METHOXYQUINAZOLIN-4(1H)-YLIDENEANILINE,Imatinib	non-pathogenic	0.00001	7311.36	C=1030, G=970		C=551/479, G=489/481	2	
chr17:37880216	G/A	G	SNV		ERBB2	exonic	1								26.80	p.Val754Met		2000	G=0.732, A=0.268		Present				+	19	NM_004448.3	c.2260G>A	missense	2.48	0.01	21.0	1.0	Furin-like cysteine rich region,Protein kinase domain,Protein tyrosine kinase,Receptor L domain								ATP binding,ErbB-3 class receptor binding,Hsp90 protein binding,RNA polymerase I core binding,apical plasma membrane,axon guidance,basal plasma membrane,basolateral plasma membrane,cell proliferation,cell surface receptor linked signaling pathway,cytoplasm,endosome membrane,enzyme linked receptor protein signaling pathway,epidermal growth factor receptor signaling pathway,epidermal growth factor-activated receptor activity,estrus,glial cell differentiation,glycoprotein binding,growth factor binding,heart development,identical protein binding,integral to membrane,lateral loop,liver development,mammary gland development,mammary gland involution,membrane raft,microvillus,motor axon guidance,myelination,negative regulation of apoptotic process,negative regulation of immature T cell proliferation in thymus,nervous system development,neuromuscular junction development,nucleotide binding,nucleus,perinuclear region of cytoplasm,peripheral nervous system development,phosphatidylinositol 3-kinase cascade,phosphatidylinositol-mediated signaling,plasma membrane,positive regulation of MAP kinase activity,positive regulation of MAPKKK cascade,positive regulation of Ras protein signal transduction,positive regulation of cell adhesion,positive regulation of cell growth,positive regulation of epithelial cell proliferation,positive regulation of phosphatidylinositol 3-kinase cascade,positive regulation of transcription from RNA polymerase I promoter,positive regulation of transcription from RNA polymerase III promoter,positive regulation of translation,postsynaptic membrane,protein C-terminus binding,protein autophosphorylation,protein binding,protein dimerization activity,protein heterodimerization activity,protein phosphatase binding,protein phosphorylation,protein tyrosine kinase activity,receptor activity,receptor complex,receptor signaling protein tyrosine kinase activity,regulation of ERK1 and ERK2 cascade,regulation of angiogenesis,regulation of microtubule-based process,regulation of transcription, DNA-dependent,response to axon injury,response to drug,response to progesterone stimulus,signal transduction,skeletal muscle tissue development,sympathetic nervous system development,tongue development,transmembrane receptor protein tyrosine kinase activity,transmembrane receptor protein tyrosine kinase signaling pathway,transmembrane signaling receptor activity,ubiquitin protein ligase binding,wound healing	Lapatinib,Trastuzumab		0.00001	2502.57	G=1464, A=536		G=732/732, A=267/269	1	
